参考文献

参考文献

［1］Finch-Jones M，Jaeck D，Mirza D，et al.Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer（EORTC intergroup trial 40983）：a randomised controlled trial［J］. Lancet，2008，371（9617）：1007-1016.

［2］Tomlinson JS，Jarnagin WR，DeMatteo RP，et al.Actual 10-year survival after resection of colorectal liver metastases defines cure［J］.J Clin Oncol，2007，25（29）：4575-4580.

［3］De Haas RJ，Wicherts DA，Andreani P，et al.Impact of expanding criteria for resectability of colorectal metastases on short-and long-term outcomes after hepatic resection［J］.Ann Surg，2011，253（6）：1069-1079.

［4］Kazaryan AM，Marangs IP，Rosok BI，et al.Laparoscoic resection of colorectal liver metastases：surgical and long-term oncologic outcome［J］.Ann Surg 2010，252（6）：1005-1012.

［5］Mayo SC，de Jong MC，Pulitano C，et al.Surgical management of hepatic neuroendocrine tumor metastasis：results from an international multi-institutional analysis［J］.Ann Surg Oncol，2010，17（12）：3129-3136.

［6］Weitz J，Blumgart LH，Fong Y，et al. Partial hepatectomy for metastases from noncolorectal，nonneuroendocrine carcinoma［J］.Ann Surg 2005，241（2）：269-276.

［7］Cannistra SA.Cancer of the ovary［J］.N Engl J Med，2004，351（24）：2519-2529.

［8］Griffiths CT.Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma［J］.Natl Cancer Inst Monogr，1975，42：101-104.

［9］Bristow RE，Tomacruz RS，Armstrong DK，et al.Survival ect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era：a metaanalysis［J］.J Clin Oncol，2002，20（5）：1248-1259.

［10］Rauh-Hain JA，Rodriguez N，Growdon W，et al.Primary debulking surgery versus neoadjuvant chemotherapy in stageⅣovarian cancer［J］.Ann Surg Oncol，2012，19（3）：959-965.

［11］Deng K，Yang C，Tan Q，et al.Sites of distant metastases and overall survival in ovarian cancer：A study of 1481 patients［J］. Gynecol Oncol，2018，150（3）：460-465.

［12］Rose PG，Piver MS，Tsukada Y，et al. Metastatic patterns in histologic variants of ovarian cancer：An autopsy study［J］.Cancer，1989，64（7）：1508-1513.

［13］Aletti GD，Podratz KC，Cliby WA，et al.StageⅣovarian cancer：disease site-specific rationale for postoperative treatment［J］.Gynecol Oncol，2009，112（1）：22-27.

［14］Brunschwig A.Hepatic lobectomy for metastatic cancer［J］.Cancer，1963，16：277-282.

［15］Bacalbasa N，Balescu I，Dima S，et al.Long-term survivors after liver resection for ovarian cancer liver metastases［J］.Anticancer Res 2015，35（12）：6919-6923.

［16］Bacalbasa N，Dima S，Brasoveanu V，et al.Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit［J］.World J Surg Oncol，2015，13（8）：235.

［17］Neumann UP，Fotopoulou C，Schmeding M，et al.Clinical outcome of patients with advanced ovarian cancer after resection of liver metastases［J］.Anticancer Res，2012，32（10）：4517-4521.

［18］Wright JD，Herzog TJ，Neugut A I，et al. Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer［J］.Obstet Gynecol，2012，120（4）：871-881.

［19］Lim MC，Kang S，Lee KS，et al.The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer［J］.Gynecol Oncol，2009，112（1）：28-34.

［20］Nakayama K，Nakayama N，Katagiri H，et al.Mechanisms of ovarian cancer metastasis：biochemical pathways［J］.Int J Mol Sci，2012，13（9）：11705-11717.

［21］Tan DS，Argarwal R，Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer［J］.Lancet Oncol，2006，7（11）：925-934.

［22］Patel CM，Sahdev A，Reznek RH.CT，MRI and PET imaging in peritoneal malignancy［J］.Cancer Imaging，2011，11（1）：123-139.

［23］Jacquet P，Sugarbaker PH.Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis［J］.Cancer Treat Res，1996，82：359-374.

［24］Saxena A，Valle SJ，Liauw W，et al.Limited synchronous hepatic resection does not compromise peri-operative outcomes or survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy［J］.J Surg Oncol，2017，115（4）：417-424.

［25］Zivanovic O，Eisenhauer EL，Zhu K，et al.The impact of bulky upper abdominal disease cephalad of the greater omentum and surgical outcome for stageⅢC epithelial ovarian，fallopian tube and primary peritoneal cancer［J］.Gynecol Oncol，2008，108（2）：287-292.

［26］Eisenhauer EL，Chi DS. Liver mobilization and diaphragm 841 peritonectomy／resection［J］.Gynecol Oncol，2007，104（2 Suppl 1）：25-28.

［27］Einekel J，Ott R，Handzel R，et al.Characteristics and management of diaphragm involvement in patients with primary advanced-stage ovarian，fallopian tube or peritoneal cancer［J］.Int J Gynecol Cancer，2009，19（7）：1288-1297.

［28］Tsolakidis D，Amant F，Van Gorp T，et al.Diaphragmatic surgery during primary debulking in 89 patients with stageⅢB-Ⅳepithelial ovarian cancer［J］.Gynecol Oncol，2010，116（3）：489-496.(https://www.daowen.com)

［29］Kato K，Katsuda T，Takeshima N.Cytoreduction of diaphragmatic metastasis from ovarian cancer with involvement of the liver using a ventral liver mobilization technique［J］.Gynecol Oncol，2016，140（3）：577-579.

［30］FIGO Committee on Gynecologic Oncology.Staging classification for cancer of the ovary，fallopian tube，and peritoneum：abridged republication of guidelines from the International Federation of Gynecology and Obstetrics（FIGO）［J］.Obstet Gynecol，2015，126（1）：171-174.

［31］O'Neill AC，Somarouthu B，Tirumani SH，et al. Patterns and prognostic importance of hepatic involvement in patients with serous ovarian cancer：a single institution experience with 244 patients［J］.Radiology，2017，282（1）：160-170.

［32］Winter WE III，Maxwell GL，Tian C，et al.Tumor residual after surgical cytoreduction in prediction of clinical outcome in stageⅣepithelial ovarian cancer：a gynecologic oncology group study［J］.J Clin Oncol，2008，26（1）：83-89.

［33］Harries M，Gore M. PartⅡ：chemotherapy for epithelial ovarian cancer-treatment of recurrent disease［J］.Lancet Oncol，2002，3（9）：537-545.

［34］Bristow RE，Montz FJ，Lagasse LD，et al.Survival impact of surgical cytoreduction in stageⅣepithelial ovarian cancer［J］.Gynecol Oncol 1999，72（3）：278-287.

［35］Kamel SI，de Jong MC，Schulick RD，et al.The role of liver-directed surgery in patients with hepatic metastasis from a gynecologic primary carcinoma［J］.World J Surg，2011，35（6）：1345-1354.

［36］Rosendahl M，Hogdall C，Mosgaard B.Restaging and survival analysis of 4036 ovarian cancer patients according to the 2013 FIGO classification for ovarian，fallopian tube，and primary peritoneal cancer［J］.Int J Gynecol Cancer，2016，26（4）：680-687.

［37］Ataseven B，Harter P，Grimm C，et al. The revised 2014 FIGO staging system for epithelial ovarian cancer：is a subclassification into FIGO stageⅣA andⅣB justified？［J］.Gynecol Oncol，2016，142（2）：243-247.

［38］Paik E，Lee Y，Lee E，et al.Survival analysis of revised 2013 FIGO staging classification of epithelial ovarian cancer and comparison with previous FIGO staging classification［J］.Obstet Gynecol，2015，58（2）：124-134.

［39］Niu GC，Shen CM，Cui W.Hepatic resection is safe for metachronous hepatic metastases from ovarian cancer［J］.Cancer Biol Med，2012，9（3）：182-187.

［40］Roh HJ，Kim DY，Joo WD，et al. Hepatic resection as part of secondary cytoreductive surgery for recurrent ovarian cancer involving the liver［J］.Arch Gynecol Obstet，2011，284（5）：1223-1229.

［41］Cowan RA，Tseng J，Murthy V，et al.Feasibility，safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer［J］.Gynecol Oncol，2017，147（2）：262-266.

［42］Rodriguez N，Miller A，Richard SD，et al. Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease：an analysis of Gynecologic Oncology Group（GOG）182［J］.Gynecol Oncol，2013，130（3）：487-492.

［43］Song YJ，Lim MC，Kang S，et al.Extended cytoreduction of tumor at the porta hepatis by an interdisciplinary team approach in patients with epithelial ovarian cancer［J］.Gynecol Oncol，2011，121（2）：253-257.

［44］Raspagliesi F，Ditto A，Martinelli F，et al.Advanced ovarian cancer：omental bursa，lesser omentum，celiac，portal and triad nodes spread as cause of inaccurate evaluation of residual tumor［J］.Gynecol Oncol，2013，129（1）：92-96.

［45］Martinez A，Pomel C，Mery E，et al.Celiac lymph node resection and porta hepatis disease resection in advanced or recurrent epithelial ovarian，fallopian tube，and primary peritoneal cancer［J］.Gynecol Oncol，2011，121（2）：258-263.

［46］Gallotta V，Fanfani F，Fagotti A，et al. Mesenteric lymph node involvement in advanced ovarian cancer patients undergoing rectosigmoid resection：prognostic role and clinical considerations［J］.Ann Surg Oncol，2014，21（7）：2369-2375.

［47］Tozzi R，Traill Z，Garruto Campanile R，et al. Porta hepatis peritonectomy and hepato-celiac lymphadenectomy in patients with stageⅢC-Ⅳovarian cancer diagnostic pathway，surgical technique and outcomes［J］.Gynecol Oncol，2016，143（1）：35-39.

［48］Gallotta V，Ferrandina G，Vizzielli G，et al.Hepatoceliac lymph node involvement in advanced ovarian cancer patients prognostic role and clinical considerations［J］.Ann Surg Oncol，2017，24（11）：3413-3421.

［49］Fasano J，Muggia F. Breast cancer arising in a BRCA-mutated background：Therapeutic implications from an animal model and drug development［J］.Ann Oncol，2009，20（4）：609-614.

［50］Gourley C，Michie CO，Roxburgh P，et al.Increased incidence of visceral metastases in scottish patients with BRCA1／2-defective ovarian cancer：an extension of the ovarian BRCAness phenotype［J］.J Clin Oncol，2010，28（15）：2505-2511.

［51］Bojalian MO，Machado GR，Swensen R，et al.Radiofrequency ablation of liver metastasis from ovarian adenocarcinoma：case report and literature review［J］.Gynecol Oncol，2004，93（2）：557-560.

［52］Cirimbei C，Prunoiu V，Marincas M，et al.Radiofrequency ablation for liver metastases-mini invasive therapeutic option for patients with unresectable tumors［in Romanian］［J］.Chirurgia（Bucur），2011，106（4）：465-473.

［53］Bleicher RJ，Allegra DP，Nora DT，et al.Radiofrequency ablation in 447 complex unresectable liver tumors：lessons learned［J］.Ann Surg Oncol，2003，10（1）：52-58.

［54］Liu B，Huang G，Jiang C，et al. Ultrasound-guided percutaneous radiofrequency ablation of liver metastasis from ovarian cancer：a singlecenter initial experience［J］.Int J Gynecol Cancer，2017，27（6）：1261-1267.

［55］Vogl TJ，Naguib NN，Lehnert T，et al. Initial experience with repetitive transarterial chemoembolization（TACE）as a third line treatment of ovarian cancer metastasis to the liver：indications，outcomes and role in patient's management［J］.Gynecol Oncol，2012，124（2）：225-229.